Science

ErVimmune develops breakthrough immunotherapies combining cancer vaccines and T-cell therapies based on the identification of new families of tumor antigens.

 

THERAPEUTIC APPROACH

HERVs as a source of tumor antigens

Human endogenous retroviruses (HERVs) represent a significant part of the human genome. HERVs are kept silent by epigenetic regulation but can be reactivated by malignant transformation or epigenetic therapies.

HERVs represent a reservoir of targetable antigens, especially in tumors with a low or moderate mutational burden.

Because HERV-derived antigens are seen as foreign, « virus-like » antigens, by the immune system, they represent relevant targets for the development of new cancer vaccines or T cell based therapies.

Our Pipeline

Our Breakthrough immunotherapies, combining cancer vaccines and T-cell therapie, have the potential to address high medical needs in oncology.

Cancer Vaccine

Discovery & Target validation

Pre-Clinical

Clinical

  • TNBC 70% 70%
  • SARCOMA 40% 40%
  • OVARIAN CANCER 40% 40%
  • AML 40% 40%
  • GLIOBLASTOMA 40% 40%

TCR-T

Discovery & Target validation

Pre-Clinical

Clinical

  • EPITOPE 1 70% 70%
  • EPITOPE 2 70% 70%
  • EPITOPE 4 40% 40%
  • EPITOPE 6 40% 40%

COLLABORATIONS & PARTNERSHIPS

Partnerships with world-class institutions

ErVimmune established strong partnerships with world-class institutions, to support its scientific innovation and development strategies, including @CRCL/Centre Léon Bérard “Development of immunotherapies targeting non-conventional tumor antigens” directed by Prof. Stéphane Depil.

To leverage ErVimmune development, a collaboration with Complete Omics (Baltimore, USA), a pioneer in proteomics, was launched on a neoantigen validation and quantification project in June 2021.

About ErVimmune

Medical research and development, in particular the development of new families of tumour antigens.

Research, development and production of monoclonal antibodies and derivatives targeting new membrane antigens and any other activity of any nature whatsoever related to the biotechnology and/or pharmaceutical industry.

Useful links

> Publications & abstracts

> Recent news

> Legal notice

Navigation

> Home

> About us

> Sciences

> Investors

> Join us

> Contact

Contact

28 RUE LAENNEC
69008 
LYON FRANCE

contact@ervimmune.com

+33 6 67 67 44 97

© 2023 ErVimmune | Next Generation Cancer Immunotherapies | Design by om&go